Lyell Immunopharma Inc (LYEL)
0.95
+0.03
(+3.64%)
USD |
NASDAQ |
Nov 22, 16:00
0.9478
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Total Liabilities (Quarterly): 88.52M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 88.52M |
| June 30, 2024 | 87.64M |
| March 31, 2024 | 91.06M |
| December 31, 2023 | 95.08M |
| September 30, 2023 | 97.42M |
| June 30, 2023 | 98.50M |
| March 31, 2023 | 96.62M |
| December 31, 2022 | 104.31M |
| Date | Value |
|---|---|
| September 30, 2022 | 157.24M |
| June 30, 2022 | 153.63M |
| March 31, 2022 | 190.85M |
| December 31, 2021 | 197.62M |
| September 30, 2021 | 211.86M |
| June 30, 2021 | 207.91M |
| March 31, 2021 | 200.27M |
| December 31, 2020 | 189.84M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
87.64M
Minimum
Jun 2024
211.86M
Maximum
Sep 2021
141.77M
Average
128.97M
Median
Total Liabilities (Quarterly) Benchmarks
| Chimerix Inc | 22.89M |
| NovaBay Pharmaceuticals Inc | 2.805M |
| Palatin Technologies Inc | 11.10M |
| iBio Inc | 6.763M |
| Theriva Biologics Inc | 15.47M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 619.22M |
| Shareholders Equity (Quarterly) | 530.70M |
| Current Ratio | 13.43 |